By Fineline Cube Bayer AG (ETR: BAYN) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) and granted Priority Review designation for its investigational oral Factor XIa (FXIa) inhibitor, asundexian, for the prevention of secondary stroke in patients following a non-cardioembolic ischemic stroke or transient ischemic attack (TIA). The NDA is supported by positive results from the Phase III OCEANIC-STROKE trial.
Regulatory Milestone
| Parameter | Detail |
|---|---|
| Agency | U.S. FDA |
| Application Type | New Drug Application (NDA) |
| Review Designation | Priority Review |
| Previous Designation | Fast Track (granted 2023) |
| Indication | Secondary stroke prevention in non-cardioembolic ischemic stroke/TIA patients |
| PDUFA Date | Expected Q4 2026 (6-month review timeline) |
| Company | Bayer AG (ETR: BAYN) |
Clinical Trial Results – OCEANIC-STROKE Phase III
| Endpoint | Outcome | Significance |
|---|---|---|
| Primary Efficacy | Time to first occurrence of ischemic stroke | Met |
| Primary Safety | Time to ISTH major bleeding | Met |
| Trial Design | Randomized, double-blind, placebo-controlled | Global study |
| Patient Population | Non-cardioembolic ischemic stroke or TIA survivors | High-risk secondary prevention cohort |
The dual success in both efficacy and safety endpoints represents a significant achievement in anticoagulation development, where balancing stroke prevention against bleeding risk has historically been challenging.
Drug Profile & Mechanism of Action
- Molecule: Oral Factor XIa (FXIa) inhibitor
- Target: Selective inhibition of Factor XIa in the coagulation cascade
- Innovation: Novel anticoagulation approach designed to prevent thrombotic events while preserving hemostasis
- Differentiation: Unlike traditional anticoagulants that target multiple coagulation factors, FXIa inhibition may offer superior safety profile with maintained efficacy
- Development Status: NDA under Priority Review; Fast Track designation previously granted in 2023
Market Context & Strategic Implications
- Secondary Stroke Prevention Market: Approximately 800,000 Americans experience stroke annually, with 25% being recurrent events; current standard of care includes antiplatelet therapy with limited efficacy
- Unmet Medical Need: Existing anticoagulants carry significant bleeding risks that limit their use in non-cardioembolic stroke populations
- Commercial Opportunity: Successful approval could position asundexian as first-in-class FXIa inhibitor for secondary stroke prevention, addressing a $3+ billion market opportunity
- Competitive Landscape: Differentiates from DOACs (direct oral anticoagulants) and antiplatelet agents through novel mechanism targeting upstream coagulation pathway
- Regulatory Strategy: Priority Review and previous Fast Track designation reflect FDA recognition of significant unmet need and promising benefit-risk profile
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory submissions, clinical trial results, and potential commercial opportunities for asundexian. Actual results may differ materially due to risks including final FDA review decisions, post-marketing safety findings, and competitive dynamics in the anticoagulation market.-Fineline Info & Tech